Associations Between Obesity and Cancer: The Role of Fatty Acid Synthase

Obesity is a common metabolic disorder and rapidly becoming a global public health problem in the 21st century. In the United States, the data from Centers for Disease Control and Prevention (CDC) indicates that about one-third (33.8%) of adults and 17% of children and adolescents were obese in 2010 (www.cdc.gov/obesity/ data/trends.html). Obesity is associated with an increased risk of several life-threatening diseases such as type 2 diabetes, cardiovascular disease, and multiple types of cancer and may represent a leading preventable cause of death (1). Recent emerging epidemiological data further reveal that obesity is also associated with poor prognosis in patients with breast and colon cancer (2,3). Obesity is characterized by body mass index (BMI), which closely represents both percentage body fat and total body fat. It is generally assumed that obesity (BMI ≥ 30 kg/m 2 ) is caused by a combination of excessive consumption of energy-dense foods such as high dietary fat and sugars, lack of physical activity, and occurs in some people because of genetic susceptibility (4). Consistent with these findings, high dietary fat intake is not only associated with obesity, diabetes, and heart disease, but also cancer, especially with colorectal, liver, breast, pancreatic, and prostate cancer (5). However, the mechanisms underlying the association of obesity with cancer are poorly understood. Excess adipose tissue is associated with metabolic changes such as reduced high-density lipoprotein cholesterol, elevated triglycerides, hypertension, and insulin resistance (1). Several site-specific mechanisms have been proposed to explain the association of obesity with organ-specific cancers. For example, obesity-induced esophageal reflux, hypertension, insulin resistance, and hormone alternations could contribute to an increased risk in esophageal, kidney, colorectal, and breast cancers, respectively. It is also widely accepted that obesity-associated inflammation contrib utes to cancer progression in several organs. In this issue of the Journal, Kuchiba et al. (6) offer an additional explanation for the association between obesity and colorectal cancer (CRC) risk in female patients. They investigated whether associations between obesity and risk of CRC varied according to lipogenic enzyme fatty acid synthase (FASN) expression in the ongoing prospective Nurses’ Health Study. FASN catalyzes fatty acid synthesis. They found that obesity (BMI ≥ 30 kg/m 2 ) was positively associated with an increased cancer risk only in the subgroup of patients whose colon tumors had no or low expression of FASN (FASN negative) compared with “normal weight” (BMI = 18.5–22.9 kg/m 2 ) individuals with FASN-negative CRC. In contrast, this association was not observed in the subgroup of patients whose colon tumors expressed FASN at moderate to high levels. Further studies are necessary to determine whether this association also exists in male CRC patients. Their findings indicate that the association of obesity with CRC may depend on cellular FASN status. Increased de novo lipogenesis contributes to increased fat mass (7). The evidence that expression and/or activity of FASN is elevated in human breast, colorectal, prostate, endometrial, ovary, and thyroid cancers (8–10) supports the hypothesis that FASN responds to exacerbated de novo fatty acid biosynthesis in tumor cells, which is essential for generating cell membranes during tumor cell proliferation (10). Kuchiba et al. (6) showed that the age-adjusted incidence rate of FASN-positive CRC is higher than FASN-negative CRC in the entire study population (n = 109 051 women). They postulated that FASN in colonic tumor epithelial cells may serve as a tumor accelerator independent of obesity based on their finding and previous observations that elevation of FASN is associated with a poor prognosis (10,11). The elevation of FASN expression in cancer is consistent with evidence that metabolism of arachidonic acid (a polyunsaturated fatty acid) by the cyclooxygenase (COX) pathway plays important roles in inflammation and cancer progression ( 12). The proinflam matory enzyme, COX-2, is elevated in up to 90% of colorectal carcinomas and 50% of adenomas (13,14), and its expression is associated with a lower survival among CRC patients (15). Similarly, COX-2 is also induced in colonic epithelium in patients with active human inflammatory bowel disease ( 16). Moreover, COX-2 levels are also elevated in other premalignant and malignant solid tumors, and its expression is associated with decreased survival among these cancer patients (17). One group of compounds, among the most promising chemopreventive agents for CRC, is nonsteroidal anti-inflammatory drugs (NSAIDs) that exert some of their anti-inflammatory and antitumor effects by targeting COX-1 and COX-2 enzymes (18). A large body of evidence from population-based studies, case–control studies, and clinical trials indicates that regular use of NSAIDs, including aspirin and selective COX-2 inhibitors, over a 10- to 15-year period reduces the relative risk of developing CRC by 40%–50% (19–21). In particular, aspirin specifically prevents the subgroup of individuals whose colon tumors express COX-2 at higher levels (22). In addition to prevention, regular aspirin use after the diagnosis of CRC at stage I, II, and III improves overall survival, especially among individuals with tumors that overexpress COX-2 (23). Therefore, metabolism of a fatty acid such as arachidonic acid by COX-2 provides one potential mechanism for explaining pro-tumor effects downstream of FASN. Based on the results of the study by Kuchiba et al. (6), which indicated that FASN-positive epithelial cells may progress